Hologic (HOLX) – FDA
-
Hologic (HOLX) Reports New Study Showing Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing
-
FDA warns of potential risk from Hologic's devices implanted in soft tissue
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to HOLX Stock Lookup